Tesofensine

PMID: 42320973

Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.

Krug O, Thomas A, Thevis M

Drug testing and analysis · 2026

PMID: 41392177

Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.

Li Yue, Meng Yufei, Li Na et al.

Nature communications · 2026

PMID: 40554466

Sex-specific effects of appetite suppressants on stereotypy in rats.

Lopez Axl, Gil-Lievana Elvi, Gutierrez Ranier

PloS one · 2025

PMID: 38656972

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

Perez Claudia I, Luis-Islas Jorge, Lopez Axel et al.

PloS one · 2024

PMID: 35294397

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Huynh Kim, Klose Marianne, Krogsgaard Kim et al.

European journal of endocrinology · 2022

PMID: 31762335

Anorectic state of obesity medications in the United States. Are leaner times ahead?

Li Xinyi, Bello Nicholas T

Expert opinion on pharmacotherapy · 2020

PMID: 32151922

New insights into potential nutritional effects of dietary saponins in protecting against the development of obesity.

Jeepipalli Syam P K, Du Bin, Sabitaliyevich Uteuliyev Y et al.

Food chemistry · 2020

PMID: 30014268

Centrally Acting Agents for Obesity: Past, Present, and Future.

Coulter Ann A, Rebello Candida J, Greenway Frank L

Drugs · 2019

PMID: 29504049

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Srivastava Gitanjali, Apovian Caroline

Current obesity reports · 2018

PMID: 26648466

Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.

Maksimov Maksim L, Svistunov Andrey A, Tarasov Vadim V et al.

Current pharmaceutical design · 2016

PMID: 25592320

The many different faces of major depression: it is time for personalized medicine.

Korte S Mechiel, Prins Jolanda, Krajnc Anne M et al.

European journal of pharmacology · 2016

PMID: 24953830

Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine.

Heal David J, Gosden Jane, Smith Sharon L

Neuropharmacology · 2015

PMID: 23784901

Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.

Bentzen Bo Hjorth, Grunnet Morten, Hyveled-Nielsen Lars et al.

Obesity (Silver Spring, Md.) · 2014

PMID: 24064009

New and emerging drug molecules against obesity.

George Melvin, Rajaram Muthukumar, Shanmugam Elangovan

Journal of cardiovascular pharmacology and therapeutics · 2014

PMID: 25114779

Safety of antiobesity drugs.

Cheung Bernard Man Yung, Cheung Tommy Tsang, Samaranayake Nithushi Rajitha

Therapeutic advances in drug safety · 2014

PMID: 23932919

Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.

Hansen Henrik H, Jensen Majbrit M, Overgaard Agnete et al.

Pharmacology, biochemistry, and behavior · 2014

PMID: 24239329

Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.

Appel Lieuwe, Bergström Mats, Buus Lassen Jørgen et al.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014

PMID: 23561987

Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2013

PMID: 23849924

Under-reporting of adverse effects of tesofensine.

Astrup Arne, Madsbad Sten, Breum Leif et al.

Lancet (London, England) · 2013

PMID: 22439841

Anti-obesity drugs: a review about their effects and their safety.

Derosa Giuseppe, Maffioli Pamela

Expert opinion on drug safety · 2012

PMID: 22085383

Serotonergic anti-obesity agents: past experience and future prospects.

Halford Jason C G, Boyland Emma J, Lawton Clare L et al.

Drugs · 2012